<DOC>
	<DOCNO>NCT01102803</DOCNO>
	<brief_summary>The purpose study investigate utility post-session administration D-cycloserine enhance fear extinction sample people acrophobia treat CBT .</brief_summary>
	<brief_title>D-Cycloserine Enhance Cognitive Behavioral Therapy ( CBT ) Acrophobia</brief_title>
	<detailed_description />
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Cycloserine</mesh_term>
	<criteria>1 . Males females 1865 year age psychiatric diagnosis acrophobia define DSMIV criterion . 2 . Willingness ability comply requirement study protocol . 1 . A lifetime history bipolar disorder , schizophrenia , psychosis , delusional disorder obsessivecompulsive disorder ; eat disorder past 6 month ; organic brain syndrome , mental retardation cognitive dysfunction could interfere capacity engage therapy ; history substance ( amphetamine , benzodiazepine , barbiturate , cocaine metabolite , marijuana , narcotic , sedative hypnotic ) abuse dependence alcohol abuse dependence ( nicotine ) last 6 month otherwise unable commit refrain alcohol use acute period study participation . 2 . Patients posttraumatic stress disorder panic disorder within past 6 month exclude . Entry patient mood anxiety disorder permit order increase accrual clinically relevant sample . Patients significant suicidal ideation ( MADRS item 10 score &gt; 3 ) enact suicidal behavior within 6 month prior intake exclude study participation refer appropriate clinical intervention . 3 . Patients must concurrent psychotropic medication ( e.g. , antidepressant , anxiolytic , beta blocker ) least 2 week prior initiation randomize treatment . 4 . Significant personality dysfunction likely interfere study participation . 5 . Serious medical illness instability hospitalization may likely within next year . 6 . Patients current past history seizure . 7 . Pregnant woman , lactate woman , woman childbearing potential use medically accept form contraception ( e.g. , IUD , oral contraceptive , barrier device , condom foam , implant progesterone rod stabilize least 3 month ) . 8 . Any concurrent psychotherapy initiate within 3 month baseline , ongoing psychotherapy duration direct specifically toward treatment acrophobia exclude . Prohibited psychotherapy include CBT therapy focus explore specific , dynamic cause phobic symptomatology provide management skill . General supportive therapy initiate &gt; 3 month prior acceptable . 9 . Prior nonresponse adequately deliver exposure ( i.e. , define patient 's report receive specific regular exposure assignment part previous treatment ) exclude participant study . 10 . Patients history head trauma cause loss consciousness , seizure ongoing cognitive impairment . 11 . Patients receive isoniazid . 12 . Patients unable understand study procedure participate inform consent process .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Phobias</keyword>
	<keyword>Anxiety Disorders</keyword>
	<keyword>D-Cycloserine</keyword>
	<keyword>Phobic Disorders</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Heights</keyword>
	<keyword>Acrophobia</keyword>
</DOC>